Ypsomed is a top developer of injection and infusion systems, so knows a lot about the difficulties that patients can face when getting to grips with these medical devices, particularly when they ...
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of ...
LONDON, Nov 22 (Reuters) - Swiss medical technology company Ypsomed's (YPSN.S), opens new tab contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next ...
GlobalData on MSN7d
“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirlNovo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.
Novo Nordisk’s (NVO) (OTCPK:NONOF) contract with Swiss medical device maker Ypsomed (OTCPK:YPHDF) includes a deal to supply injection pens for Danish drugmaker’s next-gen obesity therapy ...
Ypsomed, which posted $556m in revenue last year, primarily develops and manufactures injection and infusion systems in the diabetes space. The company sold its pen needles and blood glucose ...
Becton, Dickinson and Company announced a strategic collaboration with Ypsomed, a developer of injection systems, to advance self-injection solutions for high-viscosity biologic drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback